Onkológia 1/2023

Immunotherapy in advanced urothelial carcinomas

This review focuses on the role of immunotherapy in patients with advanced urothelial carcinomas. The introductory part is devoted to first-line platinum-based chemotherapy, characteristics of cisplatin unfit patients, and the prognostic factors, which are generally accepted. The second part mainly presents the result analysis of the study with maintenance avelumab in patients who did not progress on induction chemotherapy. The last part of this article is focused on the results of studies with immunotherapy after progression on combined chemotherapy, and there is a summary of the current recommendations for advanced urothelial carcinoma treatment in conclusion.

Keywords: advanced urothelial carcinoma, cisplatin, avelumab, pembrolizumab, atezolizumab